Table 2.

Glycemic control parameters and insulin doses during the study

mITT population Parameter	Subgroup 1 (N = 10)		Subgroup 2 (N = 10)
	Treatment period 1 Gla-300	Treatment period 2 Gla-100	Treatment period 1 Gla-100	Treatment period 2 Gla-300
HbA1c, % (mmol mol−1)
Start of treatment perioda	8.49 (69.3)	8.21 (66.2)	7.93 (63.2)	7.66 (60.2)
End of treatment periodb	8.21 (66.2)	7.96 (63.5)	7.66 (60.2)	7.53 (58.8)
Laboratory-measured FPG, mmol L−1 (mg dL−1)
Start of treatment perioda	8.34 (150.2)	8.70 (156.8)	7.25 (130.6)	7.22 (130.1)
End of treatment periodb	8.70 (156.8)	6.61 (119.0)	7.22 (130.1)	7.79 (140.3)
Mean daily basal insulin dose, U day−1 (U kg−1 day−1)
Start of treatment perioda	14.85 (0.23)	18.40 (0.29)	11.70 (0.21)	12.75 (0.23)
End of treatment periodb	18.13 (0.29)	18.10 (0.28)	13.14 (0.23)	14.53 (0.26)
Mean daily mealtime insulin dose, U day−1 (U kg−1 day−1)
Start of treatment perioda	30.60 (0.48)	29.80 (0.46)	24.90 (0.43)	25.40 (0.44)
End of treatment periodb	29.90 (0.46)	29.59 (0.45)	24.50 (0.43)	25.24 (0.44)
Mean daily total insulin dose, U day−1 (U kg−1 day−1)
Start of treatment perioda	45.45 (0.71)	48.20 (0.75)	36.60 (0.64)	38.15 (0.67)
End of treatment periodb	48.03 (0.75)	47.69 (0.74)	37.64 (0.66)	39.77 (0.70)
Ratio of daily basal to total insulin dosec
Start of treatment perioda	0.33	0.38	0.32	0.33
End of treatment periodb	0.38	0.38	0.35	0.37

FPG fasting plasma glucose, Gla-300 insulin glargine 300 U mL⁻¹, Gla-100 insulin glargine 100 U mL⁻¹, HbA _1c glycated hemoglobin, mITT modified intent-to-treat

Data presented as the mean from all participants; ^a Start of treatment period represents Day 1 in treatment period 1 and Day 29 in treatment period 2; ^b End of treatment period represents Day 28 in treatment period 1 and Day 56 in treatment period 2; ^c calculated from U day⁻¹ values